Cardiol Therapeutics Inc (NASDAQ: CRDL)’s stock price has gone decline by -4.30 in comparison to its previous close of 1.86, however, the company has experienced a -10.55% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-11-13 that NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) — PRISM MarketView, a leading provider of market insights and company news, proudly announces that Cardiol Therapeutics Inc. (NASDAQ: CRDL, TSX: CRDL) has been added to the PRISM Emerging Biotech Index, which spotlights companies leading innovation and creating market impact within the biotech sector. Cardiol’s focus on anti-inflammatory and anti-fibrotic therapies for heart disease, including its lead candidate CardiolRx™, positions it as a pioneer in addressing major unmet needs in cardiac care.
Is It Worth Investing in Cardiol Therapeutics Inc (NASDAQ: CRDL) Right Now?
CRDL has 36-month beta value of 0.95. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CRDL is 66.17M, and currently, short sellers hold a 1.50% ratio of that float. The average trading volume of CRDL on November 15, 2024 was 430.29K shares.
CRDL’s Market Performance
The stock of Cardiol Therapeutics Inc (CRDL) has seen a -10.55% decrease in the past week, with a -8.25% drop in the past month, and a -8.72% fall in the past quarter. The volatility ratio for the week is 7.59%, and the volatility levels for the past 30 days are at 5.87% for CRDL.. The simple moving average for the past 20 days is -5.99% for CRDL’s stock, with a -8.60% simple moving average for the past 200 days.
Analysts’ Opinion of CRDL
Many brokerage firms have already submitted their reports for CRDL stocks, with ROTH MKM repeating the rating for CRDL by listing it as a “Buy.” The predicted price for CRDL in the upcoming period, according to ROTH MKM is $10 based on the research report published on June 26, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see CRDL reach a price target of $9. The rating they have provided for CRDL stocks is “Buy” according to the report published on April 22nd, 2024.
CRDL Trading at -10.81% from the 50-Day Moving Average
After a stumble in the market that brought CRDL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.95% of loss for the given period.
Volatility was left at 5.87%, however, over the last 30 days, the volatility rate increased by 7.59%, as shares sank -7.55% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.01% lower at present.
During the last 5 trading sessions, CRDL fell by -10.80%, which changed the moving average for the period of 200-days by +49.16% in comparison to the 20-day moving average, which settled at $1.8932. In addition, Cardiol Therapeutics Inc saw 111.10% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CRDL
The total capital return value is set at -2.05. Equity return is now at value -106.90, with -78.91 for asset returns.
Currently, EBITDA for the company is -29.59 million with net debt to EBITDA at 0.76. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.39.
Conclusion
To put it simply, Cardiol Therapeutics Inc (CRDL) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
